KRAS and neoplasm: One subset consists of K-Ras mutation (mutK-Ras) in primary tumor to wild-type K-Ras (wtK-Ras) in metastatic form (8.8%), whereas the second subset consists of wtK-Ras in primary tumors to mutK-Ras in metastatic form (21.1%).